Drug Profile

Rilogrotug - AVEO Oncology

Alternative Names: anti-GDF15 IgG1 mAb; Anti-GDF15 mAb; AV-380

Latest Information Update: 07 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator St Vincents Hospital, Sydney
Developer AVEO Oncology
Class Monoclonal antibodies
Mechanism of Action Growth differentiation factor 15 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Cachexia

Most Recent Events

07 Oct 2024 Phase- I development for Cachexia is ongoing in USA (AVEO Oncology pipeline, October 2024)
28 Feb 2024 No recent reports of development identified for phase-I development in Cachexia in USA (IV, Infusion)
13 Jun 2023 AVEO Oncology initiates a phase I trial in Cachexia in USA (IV, Infusion) (NCT05865535)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com